Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib versus single-agent chemotherapy as third-line treatment for advanced NSCLC
2014-001207-42Phase 3Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erlotinib, gemcitabine and vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Overall survival. Started Apr 2014; status: terminated.
02
Drugs
erlotinibgemcitabinevinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-001207-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001207-42.